KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Payables (2016 - 2025)

Historic Payables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $461.7 million.

  • Vertex Pharmaceuticals' Payables rose 1179.18% to $461.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $461.7 million, marking a year-over-year increase of 1179.18%. This contributed to the annual value of $461.7 million for FY2025, which is 1179.18% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Payables of $461.7 million as of Q4 2025, which was up 1179.18% from $420.3 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Payables registered a high of $461.7 million during Q4 2025, and its lowest value of $126.9 million during Q3 2022.
  • Moreover, its 5-year median value for Payables was $339.6 million (2024), whereas its average is $303.3 million.
  • Its Payables has fluctuated over the past 5 years, first surged by 19621.75% in 2023, then plummeted by 966.94% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Payables stood at $195.0 million in 2021, then surged by 55.85% to $303.9 million in 2022, then grew by 20.07% to $364.9 million in 2023, then increased by 13.18% to $413.0 million in 2024, then rose by 11.79% to $461.7 million in 2025.
  • Its last three reported values are $461.7 million in Q4 2025, $420.3 million for Q3 2025, and $442.3 million during Q2 2025.